Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Articles

Exploring the Growing Demand and Evolving Marke...

The landscape of technology has indelibly reshaped various industries, and the healthcare sector stands as a prime beneficiary, especially evident in the profound innovation and intense development...

Dec 20, 2023

expanding-market-of-complement-inhibitor
The Expanding Market of Complement Inhibitors

The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...

Find More
lyfgenia-or-casgevy-for-sickle-cell-disease-treatment
Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

History has been created as the world captures the significance of the FDA’s approval of Casgevy (exa-cel), a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease (SCD). This groundbreaking therapy represents a long-awaited potential cure for the debilitatin...

Find More
Cardiac Rhythm Management Devices Market Analysis
Understanding the Growth and the Evolving Market Dynamics of Cardiac Rhythm Management Devices

Globally, cardiovascular diseases (CVDs) stand as the primary cause of mortality, claiming an estimated 17.9 million lives in 2019 alone, which accounted for 32% of all global deaths. Among these fatalities, a staggering 85% were attributed to heart attacks and strokes. Within the spectrum of noncommunicable diseas...

Find More

More Views & Analysis

jaypirca-for-chronic-lymphocytic-leukemia
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly’s Jaypirca. This approval is...

Find More

unlocking-the-future-of-hematology-ash-2023-preview
Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!

The upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023 is just around the corner, and leading pharmaceutical giants like BMS, Genmab, AstraZeneca, Regeneron, BeiGene, ADC Therapeutics, Eli Lilly and Company, Janssen, and others are gearing up for this conference. This conference w...

Find More

ixchiq-first-ever-chikungunya-vaccine
Valneva’s Ixchiq: First-Ever Chikungunya Vaccine

Over the past 15 years, an estimated 5 million cases of chikungunya have surfaced globally. This virus poses an escalating menace, having affected over half of the world’s nations. Recent cases in Spain, Italy, and France underscore its widespread reach. Additionally, the virus has expanded to new geographical area...

Find More

Implantable Drug Delivery Devices Market Outlook
Assessing the Emerging Trends in the Evolving Implantable Drug Delivery Device Landscape

The Implantable Drug Delivery Device market has experienced a monumental surge driven by an amalgamation of technological innovation, burgeoning demand, and the strategic maneuvers of key industry players. According to DelveInsight's latest assessment, the global Implantable Drug Delivery Device Market is poised to...

Find More

dermatomyositis-treatment
Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives

Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. It markedly affects the quality of life for individuals afflicted, as well as the well-being of their families. According to DelveInsight estimates in the latest Dermatomyositis Epidemiol...

Find More

stelara-biosimilar-wezlana
Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...

Find More

Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification .....

Find More

Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yiel.....

Find More

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also a.....

Find More

Medical device manufacturing and development is a high-capital demanding endeavor and therefore the .....

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More

The convergence of technologies and the increasing integration of medical devices to computer networ.....

Find More